Yervoy (ipilimumab) is a medication used to treat advanced melanoma, a type of skin cancer. It works by stimulating the immune system to attack cancer cells. According to the official website of Bristol Myers Squibb, the manufacturer of Yervoy, patients with Medicare may be eligible for financial assistance to help cover the cost of the medication. The company offers several programs to help patients pay for their medicines, including the Bristol Myers Squibb Patient Assistance Foundation and the Bristol Myers Squibb Access Support program.
The Bristol Myers Squibb Patient Assistance Foundation provides free medications to eligible patients who do not have insurance coverage or who cannot afford their medications. To be eligible, patients must meet certain income and insurance criteria. The Bristol Myers Squibb Access Support program provides assistance to patients who have commercial insurance but are struggling to afford their medications. The program offers co-pay assistance and other financial support to eligible patients.
According to Medicare.gov, Medicare Part B covers certain cancer treatments, including chemotherapy and other drugs administered in a doctor's office or outpatient setting. However, Medicare Part B does not cover medications that patients take at home, such as Yervoy. Patients with Medicare who need help paying for Yervoy may be eligible for assistance through the Bristol Myers Squibb programs mentioned above.
In conclusion, patients with Medicare may be eligible for financial assistance to help cover the cost of Yervoy. The Bristol Myers Squibb Patient Assistance Foundation and the Bristol Myers Squibb Access Support program offer assistance to eligible patients who cannot afford their medications. However, it is important for patients to check their eligibility and coverage with their healthcare provider and insurance provider before seeking financial assistance.
Sources:
[1] https://www.bms.com/patient-and-caregivers/get-help-paying-for-your-medicines.html
[2] https://www.medicare.gov/Pubs/pdf/11931-Cancer-Treatment-Services.pdf
[3] https://www.drugpatentwatch.com/p/biologics/tradename/YERVOY